GlassScriptPhysician profile
Alisha M Mavis
NPI 1053583823
$398,436.51
in general payments reported to CMS, 2019-2025
9 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Pediatric Transplant Hepatology providers received nationally (typical 2025 total: $425).
See the full distribution for Pediatric Transplant Hepatology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,203 · 2021: $6,922 · 2022: $27K · 2023: $172K · 2024: $104K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $155K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Travel and Lodging: $49K · Food and Beverage: $6,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $155,111.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,847.70 |
| Travel and Lodging | $49,154.92 |
| Food and Beverage | $6,748.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $146,851.68 | 2022-2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $121,427.62 | 2023-2025 | Bylvay |
| Albireo Pharma, INC. | $76,028.94 | 2022-2023 | Bylvay |
| Alexion Pharmaceuticals, INC. | $39,816.46 | 2019-2025 | Kanuma, Strensiq |
| Genzyme Corporation | $7,035.00 | 2021-2024 | |
| Echosens North America, INC. | $6,177.62 | 2022-2025 | Fibroscan, Fibroscan |
| Ipsen Pharma Sas | $960.00 | 2025 | |
| Intercept Pharmaceuticals, INC. | $124.96 | 2019 | |
| Travere Therapeutics, INC. | $14.23 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Mavis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.